Clinical trials: PD-1 Inhibitors
Non-small Cell Lung Cancer Metastatic, Brain Metastases
Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases
This is a prospective, single-center observational clinical study aimed at the efficacy and safety of radiotherapy combined with PD-1 inhibitors and chemotherapy in the treatment of Chinese patients with symptomatic NSCLC with…
- Trial name
- NCT05638425
- Testing
- Radiotherapy combined with PD-1 inhibitors
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xiangya Hospital of Central South University
Gastric Cancer With Liver Metastases
TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.
This study is a multicenter, single-arm prospective clinical trial designed to evaluate the efficacy of TACE combined with thermal ablation, antibody-drug conjugates, immune checkpoint inhibitors, and first-line chemotherapy for…
- Trial name
- NCT07602140
- Testing
- TACE combined with thermal ablation, Targeted Therapy, Immunotherapy
- Volunteers
- 40 people
- Sponsor
- Shandong Provincial Hospital
Non Small Cell Lung Cancer
An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment
After the treatment of advanced non-small cell lung cancer with immune checkpoint inhibitor PD-1/PD-L1 monoclonal antibody, if the treatment response of complete response (CR) or partial response (PR) can be achieved in the early…
- Trial name
- NCT05486650
- Testing
- PD-1 inhibitor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xinqiao Hospital of Chongqing
Melanoma
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
The purpose of this study was to evaluate safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with BRAF V600 mutant, unresectable…
- Trial name
- COMBI-i (NCT02967692)
- Testing
- Spartalizumab, Dabrafenib, Trametinib
- Where
- 179 sites in United States, Argentina and 27 more
- Volunteers
- 568 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC
The goal of this observational study is to test in advanced non-small cell lung cancer patients with negative driver gene. For these patients, PD1 antibody therapy combined with chemotherapy was the preferred regimen.
- Trial name
- NCT05878028
- Testing
- L-TIL, Tislelizumab, Docetaxel
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Quanli Gao
Advanced Pancreatic Ductal Adenocarcinoma
ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.
This study is testing whether adding three drugs, All-Trans Retinoic Acid (ATRA), SDK002 (also called Arsenic Trioxide or ATO), and tislelizumab, to standard chemotherapy is safe for people with advanced pancreatic cancer.
- Trial name
- ATARI-PDAC (NCT07348107)
- Testing
- ATRA, Arsenic Trioxide (ATO), Gemcitabine
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Daniel Breadner
Objective Response Rate
Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors
This is an intervention study, aiming to use high and low dose radiotherapy combined with PD-1/PD-L1 inhibitor combined with GM-CSF to observe the effect of anti-tumor immunity and long-term therapeutic response rate, and to…
- Trial name
- NCT05760196
- Testing
- GM-CSF
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Xiangpan Li
Personalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy, Gastrointestinal Tumors
Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment
Evaluating the efficacy and safety of Neoantigen Personalized Cancer Vaccine deepGeneAI-001 in combination with Sintilimab in the treatment of Gastrointestinal Solid Tumors
- Trial name
- PCV-GSTT (NCT07067385)
- Testing
- Neoantigen Personalized Cancer Vaccine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Locally Advanced Cervical Carcinoma, Concurrent Chemoradiotherapy
Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer
To explore the safety and efficacy of Albumin-Bound Paclitaxel/Platinum based concurrent chemoradiotherapy Followed by PD-1 inhibitor (Sintilimab) in locally advanced cervical cancer
- Conditions
- Locally Advanced Cervical Carcinoma, Concurrent Chemoradiotherapy, Immunotherapy
- Trial name
- NCT06391190
- Testing
- Albumin-Bound Paclitaxel, cisplatin, Sintilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Esophageal Neoplasms
Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer
This is a randomized, double-blind, placebo-controlled phase II clinical trial designed to evaluate whether adding omega-3 fatty acids improves outcomes in adult patients with recurrent or metastatic esophageal cancer receiving…
- Trial name
- ESO-Shanghai28 (NCT07272382)
- Testing
- PD-1 + Omega-3 Fatty Acids (EPA/DHA)
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Fudan University
Advanced Cancer
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
This study is a multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AGEN1777 as a single agent and when used in combination with a PD-1 inhibitor in participants with…
- Trial name
- NCT05025085
- Testing
- AGEN1777, a PD-1 inhibitor
- Where
- 11 sites in United States
- Volunteers
- 25 people
- Sponsor
- Agenus Inc.
Liver Metastases, Non-Small Cell Lung Cancer
Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
This study aims to evaluate the effectiveness and safety of combining low-dose radiotherapy to the intestines with immune checkpoint inhibitors (ICIs) in patients with liver metastases from solid tumors.
- Conditions
- Liver Metastases, Non-Small Cell Lung Cancer, Colorectal Cancer (Diagnosis), Pancreatic Cancer Metastatic
- Trial name
- ILDR-ICI-LM (NCT07875465)
- Testing
- Intestinal Low-Dose Radiotherapy (ILDR), PD-1/PD-L1 inhibitors, Combined Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Bing Xia
Esophageal Squamous Cell Carcinoma (ESCC), PD-1 Inhibitors
IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)
This is a single-center, prospective, single-arm Phase II clinical study to evaluate the efficacy and safety of IBI110 in combination with Sintilimab in subjects with advanced or metastatic esophageal squamous cell carcinoma…
- Trial name
- NCT06078657
- Testing
- IBI110+Sintilimab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Locally Advanced Solid Tumor, Metastatic Cancer
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT03881488
- Testing
- CTX-471, Pembrolizumab (KEYTRUDA®)
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Compass Therapeutics
Nasopharyngeal Carcinoma, Neoadjuvant Therapy
PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this Phase II, Multicenter, Randomized Controlled Clinical Trial is to evaluate the efficacy and safety of PD-1 inhibitor Plus GP chemotherapy as Neoadjuvant Therapy in the Treatment of Locoregionally Advanced…
- Conditions
- Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor
- Trial name
- NeoTurbo (NCT05340270)
- Testing
- PD-1 inhibitor+GP, GP
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Guangxi Medical University
Cancer
A Study to Assess the Safety and Efficacy of UNO - Ultra High Concentration Nitric Oxide Injection in Combination With PD-1 Inhibitors Into Unresectable Solid Primary or Metastatic Tumors
This is a Phase 1, open-label, dose-escalation and dose-expansion study comprised of 2 parts: Phase 1a - a single treatment session, an evaluation period of 21±3 days, and safety and survival follow-up period of up to 12 weeks…
- Trial name
- NCT05351502
- Testing
- Nitric Oxide 25,000 ppm, Nitric Oxide 50,000 ppm
- Where
- 4 sites in Israel
- Volunteers
- 38 people
- Sponsor
- Beyond Air Inc.
Non Small Cell Lung Cancer, Triple Negative Breast Cancer
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
- Conditions
- Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
- Trial name
- NCT03504488
- Testing
- CAB-ROR2-ADC, PD-1 inhibitor
- Where
- 59 sites in United States, Greece and 4 more
- Volunteers
- 132 people
- Sponsor
- BioAtla, Inc.
Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms
Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC
This phase II study evaluates the efficacy and safety of neoadjuvant chemoimmunotherapy consisting of camrelizumab (PD-1 inhibitor), paclitaxel, and carboplatin in patients with resectable locally advanced (Stage III-IVA)…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Oral Cavity Neoplasm
- Trial name
- NeoCamre-HN (NCT07400094)
- Testing
- Camrelizumab, Paclitaxel, carboplatin
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Immune Checkpoint Inhibitors, Anti-programmed Death-1 Antibody
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
This study is to investigate retrospectively the effects of combination of immune checkpoint inhibitors anti-programmed death-1 antibody (PD-1 antibody) and radiotherapy for recurrent, metastatic and persistent advanced cervical…
- Conditions
- Immune Checkpoint Inhibitors, Anti-programmed Death-1 Antibody, Radiotherapy, Recurrent Cervical Carcinoma
- Trial name
- NCT05310305
- Testing
- Radiotherapy for targeted lesions and PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lei Li
Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of liposomal irinotecan combined with enlonstobart in patients with platinum-resistant recurrent ovarian…
- Conditions
- Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers, Epithelial Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT07591831
- Testing
- Liposomal Irinotecan
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital